GFAP and frontotemporal dementia Frontotemporal dementia is a heterogeneous entity with variable clinical manifestations. As a consequence, it can be confused with psychiatric diseases or other neurodegenerative diseases such as Alzheimer’s disease. Despite the advances in the diagnosis of frontotemporal dementia in the last two decades, we still do not have a precise marker for … Read more
Plasma biomarkers Scientists worldwide are immersed in the race for accurate, non-invasive and accessible biomarkers to detect and diagnose Alzheimer’s Disease. To date, major scientific advances allowed the identification of several biomarkers in cerebrospinal fluid or using positron emission tomography (PET). Yet, these methods are either invasive or expensive and not easily accessible to all … Read more
Blood biomarkers for Alzheimer’s disease Recent developments in blood markers have made possible to track the different pathophysiological processes that occur in Alzheimer’s disease through plasma analysis. Our study “Use of plasma biomarkers for AT (N) classification of neurodegenerative dementias” evaluates three of these markers and has recently been published in the Journal of Neurology, … Read more
Atrophy and frontotemporal dementia The behavioral variant of frontotemporal dementia is a frequent cause of neurodegenerative dementia and the first cause of Frontotemporal Lobular Degeneration. Patients with the behavioral variant of frontotemporal dementia present a progressive personality change that begins years before diagnosis and can be confused with other neurodegenerative and psychiatric diseases. Identifying atrophy … Read more
The Sant Pau Memory Unit publishes a new study in collaboration with the University of California San Francisco. The study examines the role of neurofilament light chain (NfL) and total tau levels in plasma for the diagnosis of frontotemporal dementia and Alzheimer’s disease. The work entitled “Plasma tau and neurofilament light in frontotemporal lobar degeneration … Read more
Alzheimer’s disease is the major cause of death in adults with Down syndrome. Thus, there is an urgent need for objective biomarkers that can improve early diagnosis and monitor progression of Alzheimer’s disease in the Down syndrome population. Our recent study, entitled “Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction … Read more